Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate and nebivolol hydrochloride, the active ingredients in Nesyrgy, are a calcium‑channel blocker and a β1‑selective beta‑blocker presented as an oral tablet for systemic use. They are prescribed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Nesyrgy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution with appropriate documentation and temperature control where required.

Nesyrgy combines a calcium‑channel blocker and a β‑blocker to treat conditions related to high blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure in adult patients. - Essential hypertension: improves blood pressure control when monotherapy is insufficient. - High blood pressure: provides dual‑mechanism therapy for better cardiovascular risk management.

Nesyrgy may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Headache: mild to moderate headache. - Peripheral edema: swelling of ankles or feet. - Dizziness: sensation of light‑headedness, especially after standing. - Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Bradycardia: abnormally slow heart rate requiring medical attention. - Allergic reaction: rash, itching, swelling, or difficulty breathing.

Before prescribing Nesyrgy, clinicians should consider several safety considerations.

- Renal impairment: adjust therapy and monitor kidney function. - Hepatic dysfunction: use with caution in patients with liver disease. - Concomitant β‑blockers: avoid excessive heart rate reduction. - Pregnancy: safety not established; weigh benefits against risks. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture.

Nesyrgy can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase plasma levels of both components. - Simultaneous use of other calcium‑channel blockers: risk of additive hypotension. - Non‑selective β‑blockers: can cause excessive bradycardia.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, monitor electrolytes. - Antihypertensive agents (ACE inhibitors, ARBs): may require dose adjustment. - Antidepressants (e.g., SSRIs): monitor for blood pressure changes.